Strontium ranelate for preventing and treating postmenopausal osteoporosis

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 4, 2006, Pages

  O'Donnell, Siobhan ^a   Cranney, Ann ^b   Wells, George A ^c   Adachi, Jonathan ^d   Reginster, Jean Yves ^e  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d ST JOSEPH S HOSPITAL   (Canada)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; ORGANOMETALLIC COMPOUND; STRONTIUM RANELATE; THIOPHENE DERIVATIVE;

BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPINE FRACTURE; CHEMICALLY INDUCED DISORDER; DIARRHEA;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; SPINAL FRACTURES; THIOPHENES; DIARRHEA;

EID: 33750105854     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005326.pub3     Document Type: Review

References (64)

1. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, de Vernejoul MC, Roces A, Reginster JY. Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. Journal of clinical endocrinology and metabolism 2002;87(5):2060-66. x-wiley/crsRef/17352584
2. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel E, Pors-Nielson S, Rizzoli R, Genant HK, Reginster J. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New england journal of medicine 2004;350(5):459-68. x-wiley/crsRef/17352586
3. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS study. Osteoporosis international 2002;13:925-31. x-wiley/crsRef/17352588
4. Reginster JY, Seeman E, de Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Diaz Curiel M, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. Journal of clinical endocrinology and metabolism 2005;90(5):2816-22. x-wiley/crsRef/17352590
5. Boivin G. Bone mineralization and mineral status. Therapie 2003;58(5):409-13. x-wiley/crsRef/17352592
6. Meunier PJ, Reginster JY. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporosis international 2003;14 Suppl(3):S66-S76. x-wiley/crsRef/17352594
7. Meunier PJ, Roux C, Seeman E, Pagalilauan G, Laya M. Strontium ranelate prevented vertebral fractures in postmenopausal women with osteoporosis. Evidence-based obstetrics and gynecology 2004;6(4):216-7. x-wiley/crsRef/17352596
8. Meunier PJ, Roux C, Seeman E, Cheung A. Strontium ranelate reduced the risk of vertebral fractures in postmenopausal women osteoporosis. Evidence-based medicine 2004;9(5):149. x-wiley/crsRef/17352598
9. Naveau B. Strontium: a new treatment for osteoporosis. Joint bone spine 2004;71(4):261-63. x-wiley/crsRef/17352600
10. Pors NS. The biological role of strontium. Bone 2004;35(3):583-8. x-wiley/crsRef/17352602
11. Reginster JY. Strontium ranelate in osteoporosis. Current pharmaceutical design 2002;8(21):1907-16. x-wiley/crsRef/17352604
12. Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporosis international 2003;14(Suppl 3):S56-S65. x-wiley/crsRef/17352606
13. Reginster JY, Deroisy R, Jupsin I. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Drugs today (Barc) 2003;39(2):89-101. x-wiley/crsRef/17352608
14. Reginster JY, Devogelaer JP. Treatment of postmenopausal osteoporosis in 2004. Revue medicale de liege 2004;59(11):633-47. x-wiley/crsRef/17352610
15. Reginster JY, Lecart MP, Deroisy R, Lousberg C. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Expert opinion on investigational drugs 2004;13(7):857-64. x-wiley/crsRef/17352612
16. Sorbera LA, Castan~er J, Leeson PA, Bayes M. Strontium ranelate: Treatment and prevention of osteoporosis bone resorption inhibitor bone formation stimulant. Drugs of the future 2003;28(4):328-35. x-wiley/crsRef/17352614
17. Uebelhart D, Frey D, Frey-Rindova P, Goerres G, Michel BA. Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium. Zeitschrift für rheumatologie 2003;62(6):512-7. x-wiley/crsRef/17352616
18. Consensus Development Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis. American journal of medicine. 672 edition. Vol. 94. 1993:561.
19. Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2. http://www.cochrane.org/resources/handbook/hbook.htm 2003.
20. Blake GM, Fogelman I. Long-term effect of strontium ranelate treatment on BMD. Journal of bone and mineral research 2005;20(11):1901-4.
21. Brown JP, Josse RG. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Canadian medical association journal 2002;167(10 Suppl):S1-34.
22. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001;29(2):176-9.
23. Burge RT, King AB, Balda E, Worley D. Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025. Value health 2003;6:574-83.
24. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996;18(6):517-23.
25. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporosis international 2000;11(7):556-61.
26. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine reviews 2002;23(4):570-8.
27. Cummings SR. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
28. D'Haese PC, Schrooten I, Goodman WG, Cabrera WE, Lamberts LV, Elseviers MM, Couttenye MM, De Broe ME. Increased bone strontium levels in hemodialysis patients with osteomalacia. Kidney International 2000;57:1107-1114.
29. Eisenberg E. The biological metabolism of strontium. In: Zipkin I, editors(s). Biological Mineralization. New York: John Wilely & Sons, 1973:435-442.
30. EMEA. PROTELOS. The committee for medicinal products for human use 2004.
31. Fleiss, JL. Statistical basis of meta-analysis. Statistical methods in medical research 1993;2(2):121-45.
32. Goeree R, O'Brien B, Petitt D, Cuddy L, Ferraz M, Adachi JD. An Assessment of the burden of illness due to osteoporosis in Canada. Journal of the society of obstetricians and gynecologists of Canada 1996;(Supplement):15-24.
33. GRADE Working Group. Grading quality of evidence and strength of recommendations. British medical journal 2005;328.
34. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British medical journal 2003;327:557-60.
35. Jackson SA, Tenenhouse A, Robertson L, the CaMos Study Group. Vertebral fracture definition from population-based data: Preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporosis international 2000;11:680-7.
36. Jadad A, Moore RA, Carroll D, Jenkinson D, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled clinical trials 1996;17:1-12.
37. Jagal S, Sherry P, Schatzker J. The impact and consequences of hip fracture in Ontario. Canadian journal of surgery 1996;39:105-11.
38. Jaglal S. Incidence and impact. In: Badley E, Williams JI, editors(s). Patterns of health care in Ontario: Arthritis and related conditions. North York: Institute for Clinical Evaluative Sciences, 1998:Chapter 8.
39. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporosis international 2004;15(11):897-902.
40. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone 2003;32:468-73.
41. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis international 2004.
42. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay RL. Proximal femur bone mineral levels of U.S. adults. Osteoporosis international 1995;5:389-409.
43. Marie PJ, Garba MT, Hott M, Miravet L. Effect of low doses of stable strontium on bone metabolism in rats. Mineral electrolyte and metabolism 1985;11(1):5-13.
44. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcfied tissue international 2001;69(3):121-9.
45. Marquis P, De La Loge C, Diaz-Curiel M, Spector T, Meunier PJ. Beneficial effects of strontium ranelate on the quality of life in patients with vertebral osteoporosis (SOTI Study). Osteoporosis international 2005;16(Suppl 3):S54 (P223).
46. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurence of osteoporotic fractures. British medical journal 1996;312:1254-9.
47. Melton LJ, III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? Journal of bone and mineral research 1992;7(9):1005-10.
48. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New england journal of medicine 2001;344(19):1434-41.
49. NIH consensus development panel on osteoporosis prevention and diagnosis. Osteoporosis prevention, diagnosis, prophylaxis and treatment. Journal of american medical association 2001;285:785-95.
50. Ortolani S, Vai S. Strontium ranelate: An increased bone quality leading to vertebral antifracture efficacy at all stages. Bone 2006;38:S19-S22.
51. Oste L, Bervoets AR, Behets GJ, Dams G, Marijnissen RL, Geryl H, Lamberts LV, Verberckmoes SC, Van Hoof VO, De Broe ME, D'Haese PC. Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats. Kidney International 2005;67:920-930.
52. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporosis fractures in the United States in 1995: report from the National Osteoporosis Foundation. Journal of bone and mineral research 1997;12:24-35.
53. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. Journal of bone and mineral research 2005;20(2):177-84.
54. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International journal of epidemiology 2002;31(1):150-3.
55. Schrooten I, Cabrera W, Goodman WG, Dauwe S, Lamberts LV, Marynissen R, Dorrine W, De Broe ME, D'Haese PC. Strontium causes osteomalacia in chronic renal failure rats. Kidney International 1998;54:448-456.
56. Schrooten I, Behets GJ, Cabrera WE, Vercauteren SR, Lamberts LV, Verberckmoes SC, Bervoets AJ, Dams G, Goodman WG, De Broe ME, D'Haese PC. Dose-dependent effects on strontium on bone of chronic renal failure rats. Kidney International 2003;63:927-935.
57. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of american medical association 1995;273(5):408-12.
58. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Annals of internal medicine 1991;115(11):837-42.
59. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359(9320):1841-50.
60. Slosman D, Provvedini DM, Meunier PJ, Delmas PD, Sebert JL, De Vernejoul MC et al. The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. Journal of clinical densitometry 1999;2:37-44.
61. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ, III. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporosis international 2001;12:1042-9.
62. Tugwell P, Shea B, Boers M, Brooks P, Simon LS, Strand V et al. Evidence-based rheumatology. BMJ Publishing Group, 2004.
63. US Department of Health and Human Service. Bone health and osteoporosis: a report of the surgeon general. Office of the Surgeon General, Rockville, and MD. 2004:1-436.
64. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organization technical report 1994;843:1-129.